IMGN - ImmunoGen GAAP EPS of -$0.24 misses by $0.03 revenue of $14.2M misses by $1.98M reiterates FY guidance

• ImmunoGen press release ( NASDAQ: IMGN ): Q2 GAAP EPS of -$0.24 misses by $0.03 .
• Revenue of $14.2M (-16.2% Y/Y) misses by $1.98M .
• ImmunoGen had $373.9 million in cash and cash equivalents as of June 30, 2022, compared with $478.8 million as of December 31, 2021.

• FINANCIAL GUIDANCE ImmunoGen’s financial guidance for 2022 remains unchanged; the Company continues to expect:

• revenues between $75 million and $85 million vs consensus of $84.68M;
• operating expenses between $285 million and $295 million; and
• cash and cash equivalents at December 31, 2022 to be between $245 million and $255 million.
• Shares +4.76% PM.

For further details see: